Evidence map›Paper›PMID 41460397›Full record

ArticleHead and neck pathology2025

Histomolecular Features of a Rare Subtype of Pleomorphic Adenoma Characterised by Abundant Lymphoid Stroma and HMGA2 Rearrangements.

Ziyad Alsugair, Seddig Momenkhan, Marie Donzel, Françoise Descotes, Daniel Pissaloux, Sandrine Paindavoine, Aurelie Houlier, Franck Tirode, Eudeline Alix, Claire Mauduit and 11 more

Abstract read
In one paragraph

Article in Head and neck pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Ziyad AlsugairDepartment of Pathology, Institut de Pathologie Multisite, CHU Sud, 165 Chemin du Grand-Revoyet, Hospices Civils de Lyon, 69310, Pierre Bénite, France.
Seddig MomenkhanDepartment of Pathology, Institut de Pathologie Multisite, CHU Sud, 165 Chemin du Grand-Revoyet, Hospices Civils de Lyon, 69310, Pierre Bénite, France.
Marie DonzelDepartment of Pathology, Institut de Pathologie Multisite, CHU Sud, 165 Chemin du Grand-Revoyet, Hospices Civils de Lyon, 69310, Pierre Bénite, France.
Françoise DescotesBiochemistry and Molecular Biology Department, CHU Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
Daniel PissalouxBiopathology Department, Centre Leon Berard, Lyon, France.
Sandrine PaindavoineBiopathology Department, Centre Leon Berard, Lyon, France.
Aurelie HoulierBiopathology Department, Centre Leon Berard, Lyon, France.
Franck TirodeTeam Genetics, Epigenetics and Biology of Sarcomas, Centre de Recherche en Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Centre Leon Berard, Université Claude Bernard Lyon 1, 69008, Lyon, France.
Eudeline AlixDepartment of Pathology, Institut de Pathologie Multisite, CHU Sud, 165 Chemin du Grand-Revoyet, Hospices Civils de Lyon, 69310, Pierre Bénite, France.
Claire MauduitDepartment of Pathology, Institut de Pathologie Multisite, CHU Sud, 165 Chemin du Grand-Revoyet, Hospices Civils de Lyon, 69310, Pierre Bénite, France.
Jonathan LopezBiochemistry and Molecular Biology Department, CHU Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
Alexandra Traverse-GlehenDepartment of Pathology, Institut de Pathologie Multisite, CHU Sud, 165 Chemin du Grand-Revoyet, Hospices Civils de Lyon, 69310, Pierre Bénite, France.
Philippe CéruseUniversité de Lyon, Université Claude Bernard, Lyon 1, Lyon, France.
Pierre PhilouzeUniversité de Lyon, Université Claude Bernard, Lyon 1, Lyon, France.
Anne ChampagnacBiopathology Department, Centre Leon Berard, Lyon, France.
Valérie Costes-MartineauDepartment of Pathology, University Hospital of Montpellier, Montpellier, France.
Yoshinao KikuchiDepartment of Pathology, Teikyo University School of Medicine, Tokyo, Japan.
Hiroshi UozakiDepartment of Pathology, Teikyo University School of Medicine, Tokyo, Japan.
Emmanuelle VazDepartment of Pathology, Hôpital Tenon, Paris, France.
Claire CastainDepartment of Pathology, University Hospital of Bordeaux, Bordeaux, France.
Nazim BenzerdjebDepartment of Pathology, Institut de Pathologie Multisite, CHU Sud, 165 Chemin du Grand-Revoyet, Hospices Civils de Lyon, 69310, Pierre Bénite, France. nazim.benzerdjeb@chu-lyon.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo describe the morphological features and explore the molecular profiles of pleomorphic adenomas (PA) with abundant lymphoid stroma and HMGA2 rearrangements, and to compare them with classic lymphadenomas, in order to identify a potential molecular and morphological overlap.

methodsFour cases of PA with abundant lymphoid stroma and HMGA2 rearrangements were identified from four different institutions in France and Japan. Their characterisation was performed through a detailed pathological, immunohistochemical, and molecular analysis.

resultsAll tumours were well-circumscribed and encapsulated, predominantly composed of ductal and tubular structures with scattered myoepithelial cells embedded within a dense lymphoid stroma rich in non-atypical lymphocytes. Immunohistochemistry was positive for CK7, p63, p40, SOX10, S100, and HMGA2, and negative for PLAG1. The Ki67 proliferation index was low. Molecular analyses revealed no MDM2 amplification and excluded EBV infection. Clonality studies confirmed a polyclonal lymphoid infiltrate. Targeted DNA and RNA sequencing found no mutation; however, three cases harboured HMGA2::WIF1 fusions and one harboured HMGA2::RPSAP52 fusion. In the transcriptomic analysis, these tumours clustered together with classic lymphadenomas, separated from other salivary gland neoplasms.

conclusionsThe present study reports four cases of pleomorphic adenoma characterised by abundant lymphoid stroma and HMGA2 rearrangements, for which transcriptomic analysis found that the lymphoid stroma shared a profile similar to that observed in lymphadenomas. Given this distinctive morphological and molecular feature, we propose the designation "lymphadenoma-like" for this novel subtype of pleomorphic adenoma.

Indexed as

Adenoma, PleomorphicHMGA2 ProteinSalivary Gland NeoplasmsAdultAgedBiomarkers, TumorFemaleGene RearrangementHumansMaleMiddle AgedBiomarkers, TumorHMGA2 ProteinHMGA2 protein, humanHMGA2 rearrangementLymphadenomaPleomorphic adenoma

Identifiers

PMID41460397
PMCPMC12748408

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.